New drug cocktail shows promise for slowing kidney disease

NCT ID NCT05856760

Completed Disease control Sponsor: Travere Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding sparsentan to a standard SGLT2 inhibitor can better protect kidneys in people with IgA nephropathy, a disease that can lead to kidney failure. 48 adults who were already on stable doses of both a blood pressure drug and an SGLT2 inhibitor took sparsentan for 28 weeks. Researchers measured changes in urine protein levels to see if kidney damage slowed down.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sparsentan (also called Filspari) combined with an SGLT2 inhibitor (a type of diabetes drug that also protects kidneys)
What this could lead to: If it works, this combination could offer a new way to slow kidney damage and delay kidney failure in people with IgA nephropathy.
What could go wrong: This is a small, early-phase study with no placebo group, so results may not be definitive. The combination may not prove more effective than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOGLOBULIN A NEPHROPATHY

Contacts and locations

Locations

Travere Investigation Site

Clifton Park, New York, 12065, United States
Travere Investigational Site

Birmingham, Alabama, 35233, United States
Travere Investigational Site

Chula Vista, California, 91910, United States
Travere Investigational Site

Garden Grove, California, 92844, United States
Travere Investigational Site

Glendale, California, 91206, United States
Travere Investigational Site

Denver, Colorado, 80230, United States
Travere Investigational Site

Boise, Idaho, 83706, United States
Travere Investigational Site

Chubbuck, Idaho, 83202, United States
Travere Investigational Site

Idaho Falls, Idaho, 83404, United States
Travere Investigational Site

Chicago, Illinois, 60611, United States
Travere Investigational Site

Evergreen Park, Illinois, 60805, United States
Travere Investigational Site

Fort Wayne, Indiana, 46804, United States
Travere Investigational Site

Kansas City, Kansas, 66160, United States
Travere Investigational Site

Louisville, Kentucky, 40205, United States
Travere Investigational Site

Shreveport, Louisiana, 71101, United States
Travere Investigational Site

Albuquerque, New Mexico, 87109, United States
Travere Investigational Site

Fresh Meadows, New York, 11365, United States
Travere Investigational Site

New York, New York, 10013, United States
Travere Investigational Site

Jacksonville, North Carolina, 28546, United States
Travere Investigational Site

New Bern, North Carolina, 28562, United States
Travere Investigational Site

Columbus, Ohio, 43210, United States
Travere Investigational Site

Philadelphia, Pennsylvania, 19104, United States
Travere Investigational Site

Columbia, South Carolina, 29203, United States
Travere Investigational Site

Dallas, Texas, 75230, United States
Travere Investigational Site

Dallas, Texas, 75246, United States
Travere Investigational Site

Hong Kong, Hong Kong
Travere Investigational Site

Kowloon, Hong Kong
Travere Investigational Site

Shatin, Hong Kong
Travere Investigational Site

Sheung Wan, Hong Kong
Travere Investigational Site

Tsuen Wan, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.